Most cited papers from CHDI Foundation

CHDI Foundation

What are the most cited papers from CHDI Foundation?

The most cited paper from CHDI Foundation is "A manifesto for reproducible science" (Marcus Robert Munafo, Brian A. Nosek, Dorothy Bishop et al., 2017), with 3,631 citations. Next come "A call for transparent reporting to optimize the predictive value of preclinical research" (1,229) and "Huntington disease: natural history, biomarkers and prospects for therapeutics" (1,036).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 103 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	A manifesto for reproducible science Marcus Robert Munafo, Brian A. Nosek, Dorothy Bishop et al. · Nature Human Behaviour Open access	10 Jan 2017	3,631
2	A call for transparent reporting to optimize the predictive value of preclinical research Story C. Landis et al. · Nature Open access	Oct 2012	1,229
3	Huntington disease: natural history, biomarkers and prospects for therapeutics Christopher A. Ross, Elizabeth Aylward, Edward J. Wild et al. · Nature Reviews Neurology Review	11 Mar 2014	1,036
4	Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review Klaus Seppi, К. Ray Chaudhuri, Miguel M Coelho et al. · Movement Disorders Open access	17 Jan 2019	1,011
5	International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease Susan Helen Fox, Regina Katzenschlager, Shen‐Yang Lim et al. · Movement Disorders Open access	23 Mar 2018	1,006
6	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data Sarah J. Tabrizi, Douglas R. Langbehn, Blair R. Leavitt et al. · The Lancet Neurology Open access	30 Jul 2009	994
7	The promise and peril of chemical probes C.H. Arrowsmith et al. · Nature Chemical Biology Open access	21 Jul 2015	864
8	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data Sarah J. Tabrizi, Rachael I. Scahill, Gail N. Owen et al. · The Lancet Neurology	9 May 2013	855
9	Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease Kirupa Sathasivam, Andreas Neueder, Theresa A. Gipson et al. · Proceedings of the National Academy of Sciences Open access	22 Jan 2013	556
10	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data Sarah J. Tabrizi, Ralf Reilmann, Raymund A.C. Roos et al. · The Lancet Neurology	8 Dec 2011	552
11	Comprehensive Behavioral and Molecular Characterization of a New Knock-In Mouse Model of Huntington’s Disease: zQ175 Liliana Menalled, Andrea E. Kudwa, Sam Miller et al. · PLoS ONE Open access	20 Dec 2012	536
12	Integrated genomics and proteomics define huntingtin CAG length–dependent networks in mice Peter Langfelder et al. · Nature Neuroscience Open access	22 Feb 2016	463
13	CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion J.-M. Lee et al. · Neurology Open access711 authors	9 Feb 2012	397
14	Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition Jeffrey L. Cummings, Jacobo E Mintzer, Henry Brodaty et al. · International Psychogeriatrics Open access	14 Oct 2014	363
15	Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities Sarah J. Tabrizi, Carlos Estevez‐Fraga, Willeke van Roon‐Mom et al. · The Lancet Neurology Open access	15 Jun 2022	338
16	Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models Liliana Menalled, Bassem F. El‐Khodor, Mélissa Patry et al. · Neurobiology of Disease Open access	22 May 2009	337
17	A biological classification of Huntington's disease: the Integrated Staging System Sarah J. Tabrizi, Scott Schobel, Emily C. Gantman et al. · The Lancet Neurology	15 Jun 2022	336
18	Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension Praveen Surendran et al. · Nature Genetics Open access212 authors	12 Sep 2016	336
19	Characterization of Neurophysiological and Behavioral Changes, MRI Brain Volumetry and 1H MRS in zQ175 Knock-In Mouse Model of Huntington's Disease Taneli Heikkinen, Kimmo K Lehtimäki, Nina E. Vartiainen et al. · PLoS ONE Open access	20 Dec 2012	327
20	Cell Type-Specific Transcriptomics Reveals that Mutant Huntingtin Leads to Mitochondrial RNA Release and Neuronal Innate Immune Activation Hyeseung Lee, Robert J. Fenster, Sergio Sebastian Pineda et al. · Neuron Open access	17 Jul 2020	306
21	Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients Edward J. Wild, Roberto Boggio, Douglas R. Langbehn et al. · Journal of Clinical Investigation Open access	5 Apr 2015	285
22	Unravelling and Exploiting Astrocyte Dysfunction in Huntington’s Disease Baljit S. Khakh, Vahri Beaumont, Roger Cachope et al. · Trends in Neurosciences ReviewOpen access	Jun 2017	267
23	The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington’s disease patients Andreas Neueder, Christian Landles, Rhia Ghosh et al. · Scientific Reports Open access	25 Apr 2017	254
24	Huntington's disease accelerates epigenetic aging of human brain and disrupts DNA methylation levels Steve Horvath, Peter Langfelder, Seung Kwak et al. · Aging Open access	27 Jul 2016	254
25	Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease Bryan Zeitler et al. · Nature Medicine	Jul 2019	224
26	Botulinum toxin type A therapy for cervical dystonia Mafalda Castelão, Raquel Marques, Gonçalo Silva Duarte et al. · Cochrane Database of Systematic Reviews Open access	12 Dec 2017	216
27	Human glia can both induce and rescue aspects of disease phenotype in Huntington disease Abdellatif Benraiss, Su Wang, Stephanie A. Herrlinger et al. · Nature Communications Open access	7 Jun 2016	205
28	Impaired TrkB Receptor Signaling Underlies Corticostriatal Dysfunction in Huntington’s Disease Joshua L. Plotkin, Michelle Day, Jayms D. Peterson et al. · Neuron Open access	Jul 2014	203
29	Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis Rachael I. Scahill et al. · The Lancet Neurology Open access	26 May 2020	199
30	Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations Shannon M. Smith et al. · Pain Open access	8 Jun 2020	197
31	Local control of striatal dopamine release Roger Cachope, Joseph Francois Cheer · Frontiers in Behavioral Neuroscience Open access	23 May 2014	195
32	Data Analytics from Enroll‐ HD , a Global Clinical Research Platform for Huntington's Disease Georg B. Landwehrmeyer, Cheryl J. Fitzer‐Attas, Joseph D. Giuliano et al. · Movement Disorders Clinical Practice Open access	22 Jun 2016	192
33	A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes Marc Ciosi, Alastair Maxwell, Sarah A. Cumming et al. · EBioMedicine Open access	Oct 2019	186
34	Matrix Metalloproteinases Are Modifiers of Huntingtin Proteolysis and Toxicity in Huntington's Disease John Preston Miller, Jennifer L. Holcomb, Ismael Al‐Ramahi et al. · Neuron Open access	Jul 2010	185
35	Task force report: Scales for screening and evaluating tremor: Critique and recommendations Rodger J. Elble, Peter G. Bain, Maria João Forjaz et al. · Movement Disorders	3 Sep 2013	185
36	HDAC4 Reduction: A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration Michał Mielcarek et al. · PLoS Biology Open access	26 Nov 2013	174
37	Treatment of restless legs syndrome: Evidence‐based review and implications for clinical practice (Revised 2017)§ Juliane Winkelmann, Richard P. Allen, Birgit Högl et al. · Movement Disorders Open access	14 May 2018	173
38	The HTT CAG-Expansion Mutation Determines Age at Death but Not Disease Duration in Huntington Disease Jae Whan Keum, Aram Shin, Tammy Gillis et al. · The American Journal of Human Genetics Open access	Feb 2016	168
39	DataLad: distributed system for joint management of code, data, and their relationship Yaroslav O. Halchenko et al. · The Journal of Open Source Software Open access	Jul 2021	165
40	Motor, cognitive, and functional declines contribute to a single progressive factor in early HD Scott Schobel et al. · Neurology Open access402 authors	15 Nov 2017	165
41	Mutant huntingtin fragmentation in immune cells tracks Huntington’s disease progression Andreas Weiss, Ulrike Träger, Edward J. Wild et al. · Journal of Clinical Investigation Open access	20 Sep 2012	155
42	Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington’s Disease Roland W. Bürli et al. · Journal of Medicinal Chemistry Open access	21 Nov 2013	152
43	Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study Stefan Klöppel, Sarah Gregory, Elisa Scheller et al. · EBioMedicine Open access	6 Aug 2015	149
44	Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force Bruno J. Vellas et al. · Alzheimer s & Dementia	26 Jun 2013	145
45	Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington’s disease Xiao‐Hong Lu et al. · Science Translational Medicine	24 Dec 2014	140
46	HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity Virginia B. Mattis, Colton M. Tom, Sergey Akimov et al. · Human Molecular Genetics Open access	3 Mar 2015	135
47	Striatal Pre- and Postsynaptic Profile of Adenosine A2A Receptor Antagonists Marco Orrù, Jana Bakešová, Marc Brugarolas et al. · PLoS ONE Open access	11 Jan 2011	132
48	Characterization of HTT Inclusion Size, Location, and Timing in the zQ175 Mouse Model of Huntington´s Disease: An In Vivo High-Content Imaging Study Nikisha Carty, Nadège Berson, Karsten Tillack et al. · PLoS ONE Open access	10 Apr 2015	128
49	A modifier of Huntington's disease onset at the MLH1 locus Jong‐Min Lee, Michael J. Chao, Denise H. Harold et al. · Human Molecular Genetics Open access	20 Jul 2017	125
50	Genetic modifiers of Huntington disease differentially influence motor and cognitive domains Jong‐Min Lee et al. · The American Journal of Human Genetics Open access	23 Mar 2022	123

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.